Derniers manuscrits de l'équipe
-
-
Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, et al.. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature Communications, 2024, 15 (1), pp.5932. ⟨10.1038/s41467-024-47000-5⟩. ⟨hal-04655437⟩
-
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, et al.. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature Communications, 2024, 15 (1), pp.5931. ⟨10.1038/s41467-024-46999-x⟩. ⟨hal-04765682⟩
-
Laetitia Collet, Brunhilde Hanvic, Margherita Turinetto, Isabelle Treilleux, Nicolas Chopin, et al.. BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. Frontiers in Oncology, 2024, 14, ⟨10.3389/fonc.2024.1354427⟩. ⟨hal-04882825⟩
-
-
Stéphane Dalle, Estelle Verronese, Axelle N’kodia, Christine Bardin, Céline Rodriguez, et al.. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. OncoImmunology, 2024, 13 (1), pp.2372118. ⟨10.1080/2162402X.2024.2372118⟩. ⟨hal-04632685⟩